Intrinsic Value of S&P & Nasdaq Contact Us

Curis, Inc. CRIS NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
49/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Curis, Inc. (CRIS) has a negative trailing P/E of -9.4, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 0.2 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -10.69%, forward earnings yield 416.67%. PEG 0.01 (Peter Lynch undervalued ≤1.0).

Criteria proven by this page:

  • VALUE (100/100, Pass) — PEG ≤ 1.0 — Peter Lynch undervalued (0.01).
  • Forward P/E 0.2 — analysts expect a return to profitability with estimated EPS of $2.73 for FY2029.
  • PEG Ratio 0.01 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
  • Trailing Earnings Yield -10.69% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 416.67% as earnings recover.

Overall SharesGrow Score: 49/100 with 2/7 criteria passed.

SharesGrow 7-Criteria Score
49/100
SG Score
View full scorecard →
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
FUTURE
90/100
Analyst consensus
→ Forecast
PAST
0/100
→ Income
HEALTH
33/100
Debt-to-Equity & liquidity
→ Health
~
MOAT
50/100
→ Income
~
GROWTH
58/100
→ Income
INCOME
10/100
→ Income

Valuation Snapshot — CRIS

Valuation Multiples
P/E (TTM)-9.4
Forward P/E0.2
PEG Ratio0.01
Forward PEG0.01
P/B Ratio12.98
P/S Ratio0.75
EV/EBITDA-0.1
Per Share Data
EPS (TTM)$-0.06
Forward EPS (Est.)$2.73
Book Value / Share$0.04
Revenue / Share$0.07
FCF / Share$-0.21
Yields & Fair Value
Earnings Yield-10.69%
Forward Earnings Yield416.67%
Dividend Yield0.00%

Historical Valuation

Year P/E (TTM) PEG Ratio P/B Ratio P/S Ratio Dividend Yield
2016 -6.8 1.40 13.97 54.34 -
2017 -2.0 0.09 4.35 10.55 -
2018 -0.7 0.02 -5.08 2.19 -
2019 -1.8 1.15 -1.66 5.64 -
2020 -13.3 0.36 3.05 36.79 -
2021 -9.6 0.50 4.81 40.93 -
2022 -0.9 -0.04 1.10 5.05 -
2023 -1.4 0.05 3.43 6.73 -
2024 -0.4 0.02 -3.22 1.77 -
2025 -17.1 0.19 23.79 13.76 -

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year EPS (Diluted) Revenue Net Income Net Margin
2016 $-45.50 $7.53M $-60.41M -802.6%
2017 $-35.75 $9.9M $-53.32M -538.7%
2018 $-19.67 $10.43M $-32.58M -312.4%
2019 $-22.18 $10M $-36.8M -367.9%
2020 $-14.33 $10.84M $-34.88M -321.9%
2021 $-11.06 $10.65M $-50.64M -475.5%
2022 $-12.92 $10.16M $-60.32M -593.6%
2023 $-8.96 $10.02M $-47.41M -473%
2024 $-6.88 $10.91M $-43.39M -397.8%
2025 $-0.58 $9.44M $-7.58M -80.3%

Analyst Estimates

Year EPS (Avg) EPS Range Revenue (Avg) Revenue Range Analysts
2026 $-0.82 $-0.92 – $-0.72 $7.55M $5.73M – $8.43M 2
2027 $-0.53 $-2.03 – $0.97 $26.5M $20.11M – $29.56M 3
2028 $-0.59 $-2.90 – $1.68 $42.14M $31.97M – $47.01M 3
2029 $2.73 $1.87 – $3.14 $119M $90.28M – $132.75M 1
2030 $3.17 $2.18 – $3.65 $152M $115.32M – $169.56M 1
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message